Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Available Omnichannel HCP Data Sources

Available Omnichannel HCP Data Sources

  • March 26, 2019
  • Posted in Lab Testing Insights

This post was last updated on December 29, 2020 at 1:44 pm

HCP Data Sources

Clinical Diagnostic Data for Omnichannel HCP Promotion Marketing: Part Two

We’re excited to share part two of our blog series about one of the most emerging themes for life science brands to harness: real world clinical diagnostics data to power HCP omni-channel marketing. We’ve broken up our series into five tranches to explore this emerging arena where early adopters are synchronizing all promotion activity based on clinical diagnostic insights for competitive advantage. If you missed the first blog, check it out here!

Part Two:  What data sources are available?

Before we dive into some key data sources, I’m going to impose a couple of filters for the purpose of this conversation. One, there are many types of data sources available within the healthcare data ecosystem such as social determinant, online search, demographics, and the emerging wearables and connected therapeutic device categories. Our focus for this blog series is the data that is used by HCPs to determine, monitor, and prescribe therapies to patients.

If we look at the treatment paradigm, it looks something like the image below:

The historical categories the life sciences industry has harnessed to understand patient populations and treating HCPs are Rx and claims data. These are proven data sources that enable value for a variety of applications such as segmentation, patient journeys, and promotional activities. These data sources have one key component in common: they have always been formatted for machine analytics, as these data types are responsible for the US healthcare complex getting paid, thus always machine readable. However, these data sources are not available while treatment decisions are being made, they are downstream after decisions are already made by HCPs. These data types answer the key question “what treatments did the patient receive?”

The newest category is lab testing, the focus here at Prognos for nearly a decade. The key question this category answers is “what is the patient’s current health status?”.This is a great question to answer for the ~70% of conditions that require lab tests to confirm diagnosis! Clinically speaking, please check out a recent blog post with exploration into non-small cell lung cancer testing here.

But here’s the rub on why lab testing category has not been historically available for machine analytics at scale: it’s a complex unformatted dataset that requires a lot of knowhow to prepare a clean structured output for analytics – take it from us, we’ve spent nearly a decade solving this problem! If you work with a data source in the space that delivers this category from a multi-lab prospective, make sure to do your due diligence to understand how that firm 1) integrates/dedupes via secure HIPAA-compliant software, 2) harmonizes the data in machine readable form, and 3) structures to harness for advanced analytics for your use case. For further reading, check out another blog post on the value of lab data here.

To make a long story short, this category is now available alongside traditional data sources to garner holistic near-real time clinical insights on patient populations and their treating HCPs. Even more compelling are the types of questions and answers life science firms glean by working with an integrated dataset that combines all available data sources. Please check out a tangible use case from a recent diabetes study (combining lab & Rx data) that Prognos completed by clicking here. Below is a helpful grid outlining a handful of those questions around the value of combining categories together for clinical diagnostic insight.

To wrap up, I believe we are in a golden age of advanced healthcare analytics where private and public institutions are pushing this industry forward. Truth is always just a matter of time. My sentiment is interoperability and structuring of clinical datasets for advanced analytics is going to yield an era of efficiency and very best patient outcomes across the entire U.S. healthcare complex.

Next up in this blog series, I’ll explore what types of deterministic and AI segments are available. We will investigate the process of matching a therapy’s indication by creating clinical patient profiles based on these data sources to take insight to action for optimized HCP promotional activities.

Contact us for more information and share your omnichannel strategy with our experts.

About the Author

Matt Apprendi has been a fixture in the NYC technology scene for more than a decade, where he’s focused on conceptualizing, building and commercializing intelligent data products. As VP of Digital Products at Prognos, Matt is responsible for unlocking the value of clinical diagnostic data to power intelligent digital applications across the greater healthcare ecosystem.

Some of Matt’s career highlights prior to Prognos include commercializing Reachable’s enterprise relationship analytics software, founding Meeting Machine, a professional networking application, helping launch Hearst’s digital data-driven marketing division Core Audience and forming the data solutions practice at digital marketing software provider Collective.

Matt proudly served in the United States Marine Corps as a Combat Correspondent and holds degrees from NYU Stern & University of South Carolina Beaufort.

« Biomarker Testing in Non-Small Cell Lung Cancer
What to Consider if Your Drug is a Targeted Therapy for a New Biomarker »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.